GALWAY, IRELAND--September 12, 2018--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Novartis is planning to build a new production plant for cell and gene therapies at its Stein site in Switzerland following approval for its chimeric antigen receptor T cell (CAR-T) cancer drug Kymriah by the European Commission (EC). Within this article: Details plant addition, investment, timeline, cancer drug approval and related drug production
(All Fields Required)
Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.
×Contact Us
For More Info!
